Equity research analysts expect Nu Skin Enterprises, Inc. (NYSE: NUS – Get a rating) will report $578.98 million in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts released earnings estimates for Nu Skin Enterprises. The lowest sales estimate is $576.30 million and the highest is $581.66 million. Nu Skin Enterprises reported sales of $677.03 million in the same quarter last year, suggesting a negative 14.5% year-over-year growth rate. The company is expected to announce its next earnings report after the market closes on Monday, January 1.
According to Zacks, analysts expect Nu Skin Enterprises to report annual sales of $2.70 billion for the current fiscal year, with estimates ranging from $2.70 billion to $2.71 billion. For next year, analysts expect the company to post sales of $2.77 billion, with estimates ranging from $2.74 billion to $2.80 billion. Zacks sales calculations are an average based on a survey of sell-side analysts who cover Nu Skin Enterprises.
Nu Skin Companies (NYSE: NUS – Get a rating) last released its quarterly results on Wednesday, February 16. The company reported EPS of $1.11 for the quarter, beating consensus analyst estimates of $0.95 by $0.16. The company posted revenue of $673.44 million in the quarter, versus analyst estimates of $655.93 million. Nu Skin Enterprises achieved a return on equity of 23.39% and a net margin of 5.46%. Nu Skin Enterprises quarterly sales decreased 10.0% compared to the same quarter last year. During the same period a year earlier, the company posted EPS of $1.40.
A number of stock analysts have recently released reports on NUS stocks. Jefferies Financial Group raised its price target on Nu Skin Enterprises shares from $61.00 to $75.00 in a Thursday, February 17 report. Zacks Investment Research upgraded Nu Skin Enterprises shares from a “hold” rating to a “strong-buy” rating and set a price target of $57.00 on the stock in a Tuesday, March 29 research report . TheStreet downgraded Nu Skin Enterprises shares from a “b” rating to a “c+” rating in a Friday, February 18 research note. StockNews.com began covering Nu Skin Enterprises shares in a report on Thursday, March 31. They have placed a “holding” rating on the stock. Finally, DA Davidson raised his price target on Nu Skin Enterprises stock from $47.00 to $50.00 and gave the stock a “neutral” rating in a Thursday, Feb. 17 research note. Four equity research analysts gave the stock a hold rating, one gave the company a buy rating and one gave the company a strong buy rating. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $61.17.
Separately, director Andrew D. Lipman sold 1,000 shares of the company in a trade dated Friday, April 22. The stock was sold at an average price of $47.72, for a total transaction of $47,720.00. Following the completion of the sale, the administrator now directly owns 71,214 shares of the company, valued at approximately $3,398,332.08. The transaction was disclosed in a document filed with the Securities & Exchange Commission, accessible via the SEC website. Additionally, CEO Ryan S. Napierski sold 25,000 shares in a trade dated Friday, February 25. The shares were sold at an average price of $47.40, for a total value of $1,185,000.00. Disclosure of this sale can be found here. In the past three months, insiders have sold 29,000 shares of the company valued at $1,383,890. Insiders of the company own 4.00% of the shares of the company.
Several hedge funds have recently increased or reduced their holdings in NUS. BlackRock Inc. increased its stake in Nu Skin Enterprises by 0.8% during the third quarter. BlackRock Inc. now owns 5,893,635 shares of the company worth $238,516,000 after purchasing an additional 46,186 shares in the last quarter. Wellington Management Group LLP increased its stake in Nu Skin Enterprises by 8.3% during the 3rd quarter. Wellington Management Group LLP now owns 3,450,392 shares of the company valued at $139,638,000 after purchasing an additional 264,454 shares in the last quarter. Renaissance Technologies LLC increased its stake in Nu Skin Enterprises by 3.4% during the third quarter. Renaissance Technologies LLC now owns 2,770,696 shares of the company valued at $112,130,000 after purchasing an additional 92,400 shares in the last quarter. Capital World Investors increased its stake in Nu Skin Enterprises by 10.0% during the third quarter. Capital World Investors now owns 1,100,000 shares of the company valued at $44,517,000 after purchasing an additional 100,000 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its holdings of Nu Skin Enterprises shares by 1.0% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 921,772 shares of the company worth $46,780,000 after purchasing an additional 9,127 shares last quarter. Institutional investors hold 80.57% of the company’s shares.
Shares of Nu Skin Enterprises Stocks opened at $45.33 on Friday. Nu Skin Enterprises has a one-year minimum of $39.40 and a one-year maximum of $62.70. The company’s 50-day simple moving average is $48.34 and its two-hundred-day simple moving average is $47.48. The company has a debt ratio of 0.29, a current ratio of 1.65 and a quick ratio of 0.89. The stock has a market capitalization of $2.26 billion, a P/E ratio of 15.91 and a beta of 1.25.
The company also recently announced a quarterly dividend, which was paid on Wednesday, March 9. Shareholders of record on Monday, February 28 received a dividend of $0.385. The ex-dividend date was Friday, February 25. This is a positive change from Nu Skin Enterprises’ previous quarterly dividend of $0.38. This represents an annualized dividend of $1.54 and a yield of 3.40%. Nu Skin Enterprises’ dividend payout ratio (DPR) is currently 54.04%.
Nu Skin Enterprises Company Profile (Get a rating)
Nu Skin Enterprises, Inc develops and distributes beauty and wellness products worldwide. It provides skin care systems, including ageLOC Spa systems, ageLOC Transformation anti-aging skin care systems and ageLOC LumiSpa skin cleansing and treatment devices; and ageLOC Boost, plus a range of other cosmetic and personal care products.
For more information on Zacks Investment Research’s research offerings, visit Zacks.com
Receive daily news and reviews for Nu Skin Enterprises – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Nu Skin Enterprises and related companies with MarketBeat.com’s free daily email newsletter.